人福医药：HW241045片药物临床试验获批准

Core Viewpoint - The company, Renfu Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its drug HW241045 for the treatment of idiopathic pulmonary fibrosis [1] Group 1 - Renfu Pharmaceutical's wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd., has been granted a clinical trial approval notice for HW241045 [1] - The approved clinical trial is specifically aimed at the indication of idiopathic pulmonary fibrosis [1]